Wall Street Expects This Growth Stock That's Already Climbed 70% to Almost Double -- And Here's Why.

▤ Summary

Intellia Therapeutics is nearing a major milestone with lonvo-z, its one-time CRISPR-based treatment for hereditary angioedema. The company reported strong phase 3 results, including an 87% reduction in attacks versus placebo and a large share of patients remaining attack-free. Intellia has started a rolling FDA submission and expects to finish it in the second half of the year. If regulators approve the therapy, the company could move into commercial-stage revenue generation next year.

▦ Linked Companies